Name: rs776746
Published: September 3, 2024
License: Open Access

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs776746

Current Build 157

Released September 3, 2024

Organism: Homo sapiens
Position: chr7:99672916 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
Alleles: T>A / T>C / T>G
Variation Type: SNV Single Nucleotide Variation
Frequency: T=0.299312 (79225/264690, TOPMED)
T=0.112628 (26293/233450, ALFA)
T=0.273288 (40738/149066, GnomAD_genomes) (+ 6 more)
T=0.25161 (19486/77444, 38KJPN)
T=0.2272 (1643/7230, Korea4K)
T=0.3846 (2463/6404, 1000G_30X)
T=0.2840 (1361/4792, PharmGKB)
T=0.3993 (753/1886, HapMap)
T=0.2249 (412/1832, Korea1K)

Clinical Significance: Reported in ClinVar
Gene : Consequence: CYP3A5 : Splice Acceptor Variant
ZSCAN25 : Intron Variant
Publications: 498 citations
Genomic View: See rs on genome

ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20231103111315

Population	Group	Sample Size	Ref Allele	Alt Allele	Ref HMOZ	Alt HMOZ	HTRZ	HWEP
Total	Global	233450	T=0.112628	C=0.887372	0.03241	0.807154	0.160437	32
European	Sub	198972	T=0.070035	C=0.929965	0.005146	0.865076	0.129777	1
African	Sub	10628	T=0.69646	C=0.30354	0.487204	0.094279	0.418517	0
African Others	Sub	356	T=0.829	C=0.171	0.679775	0.022472	0.297753	0
African American	Sub	10272	T=0.69188	C=0.30812	0.48053	0.096768	0.422702	0
Asian	Sub	822	T=0.287	C=0.713	0.080292	0.506083	0.413625	0
East Asian	Sub	644	T=0.278	C=0.722	0.07764	0.521739	0.400621	0
Other Asian	Sub	178	T=0.320	C=0.680	0.089888	0.449438	0.460674	0
Latin American 1	Sub	976	T=0.289	C=0.711	0.086066	0.508197	0.405738	0
Latin American 2	Sub	9006	T=0.2041	C=0.7959	0.048634	0.640462	0.310904	5
South Asian	Sub	5062	T=0.2501	C=0.7499	0.070723	0.570525	0.358751	3
Other	Sub	7984	T=0.1671	C=0.8329	0.052355	0.718186	0.229459	32

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download

Study	Population	Group	Sample Size	Ref Allele	Alt Allele
TopMed	Global	Study-wide	264690	T=0.299312	C=0.700688
Allele Frequency Aggregator	Total	Global	233450	T=0.112628	C=0.887372
Allele Frequency Aggregator	European	Sub	198972	T=0.070035	C=0.929965
Allele Frequency Aggregator	African	Sub	10628	T=0.69646	C=0.30354
Allele Frequency Aggregator	Latin American 2	Sub	9006	T=0.2041	C=0.7959
Allele Frequency Aggregator	Other	Sub	7984	T=0.1671	C=0.8329
Allele Frequency Aggregator	South Asian	Sub	5062	T=0.2501	C=0.7499
Allele Frequency Aggregator	Latin American 1	Sub	976	T=0.289	C=0.711
Allele Frequency Aggregator	Asian	Sub	822	T=0.287	C=0.713
gnomAD v4 - Genomes	Global	Study-wide	149066	T=0.273288	C=0.726712
gnomAD v4 - Genomes	European	Sub	78624	T=0.06844	C=0.93156
gnomAD v4 - Genomes	African	Sub	41412	T=0.69528	C=0.30472
gnomAD v4 - Genomes	American	Sub	15276	T=0.22054	C=0.77946
gnomAD v4 - Genomes	East Asian	Sub	5168	T=0.2765	C=0.7235
gnomAD v4 - Genomes	South Asian	Sub	4822	T=0.3005	C=0.6995
gnomAD v4 - Genomes	Ashkenazi Jewish	Sub	3470	T=0.0824	C=0.9176
gnomAD v4 - Genomes	Middle Eastern	sub	294	T=0.105	C=0.895
38KJPN	JAPANESE	Study-wide	77444	T=0.25161	C=0.74839
Korean Genome Project 4K	KOREAN	Study-wide	7230	T=0.2272	C=0.7728
1000Genomes_30X	Global	Study-wide	6404	T=0.3846	C=0.6154
1000Genomes_30X	African	Sub	1786	T=0.8175	C=0.1825
1000Genomes_30X	Europe	Sub	1266	T=0.0545	C=0.9455
1000Genomes_30X	South Asian	Sub	1202	T=0.3419	C=0.6581
1000Genomes_30X	East Asian	Sub	1170	T=0.2786	C=0.7214
1000Genomes_30X	American	Sub	980	T=0.201	C=0.799
PharmGKB Aggregated	Global	Study-wide	4792	T=0.2840	C=0.7160
PharmGKB Aggregated	PA136096713	Sub	2128	T=0.2669	C=0.7331
PharmGKB Aggregated	PA130243626	Sub	462	T=0.221	C=0.779
PharmGKB Aggregated	PA149793606	Sub	348	T=0.333	C=0.667
PharmGKB Aggregated	PA131953488	Sub	274	T=0.339	C=0.661
PharmGKB Aggregated	PA131954059	Sub	274	T=0.339	C=0.661
PharmGKB Aggregated	PA164946097	Sub	262	T=0.740	C=0.260
PharmGKB Aggregated	PA142196590	Sub	194	T=0.263	C=0.737
PharmGKB Aggregated	PA136110459	Sub	184	T=0.179	C=0.821
PharmGKB Aggregated	PA156029446	Sub	158	T=0.259	C=0.741
PharmGKB Aggregated	PA130150648	Sub	154	T=0.091	C=0.909
PharmGKB Aggregated	PA131638180	Sub	132	T=0.121	C=0.879
PharmGKB Aggregated	PA155625256	Sub	66	T=0.23	C=0.77
PharmGKB Aggregated	PA130150889	Sub	58	T=0.16	C=0.84
PharmGKB Aggregated	PA151371514	Sub	40	T=0.23	C=0.78
PharmGKB Aggregated	PA131649870	Sub	36	T=0.11	C=0.89
PharmGKB Aggregated	PA130491309	Sub	22	T=0.14	C=0.86
HapMap	Global	Study-wide	1886	T=0.3993	C=0.6007
HapMap	American	Sub	766	T=0.238	C=0.762
HapMap	African	Sub	692	T=0.715	C=0.285
HapMap	Asian	Sub	252	T=0.266	C=0.734
HapMap	Europe	Sub	176	T=0.051	C=0.949
Korean Genome Project	KOREAN	Study-wide	1832	T=0.2249	C=0.7751

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements

Sequence name	Change
GRCh38.p14 chr 7	NC_000007.14:g.99672916T>A
GRCh38.p14 chr 7	NC_000007.14:g.99672916T>C
GRCh38.p14 chr 7	NC_000007.14:g.99672916T>G
GRCh37.p13 chr 7	NC_000007.13:g.99270539C>T
GRCh37.p13 chr 7	NC_000007.13:g.99270539C>A
GRCh37.p13 chr 7	NC_000007.13:g.99270539C>G
CYP3A5 RefSeqGene (LRG_1431)	NG_007938.2:g.12083A>T
CYP3A5 RefSeqGene (LRG_1431)	NG_007938.2:g.12083A>G
CYP3A5 RefSeqGene (LRG_1431)	NG_007938.2:g.12083A>C

Gene: CYP3A5, cytochrome P450 family 3 subfamily A member 5 (minus strand)

Molecule type	Change	Amino acid[Codon]	SO Term
CYP3A5 transcript variant 4	NM_001291829.2:c.	N/A	Splice Acceptor Variant
CYP3A5 transcript variant 1	NM_000777.5:c.219-237A>T	N/A	Intron Variant
CYP3A5 transcript variant 2	NM_001190484.3:c.219-237A… NM_001190484.3:c.219-237A>T	N/A	Intron Variant
CYP3A5 transcript variant 5	NM_001291830.2:c.189-237A… NM_001291830.2:c.189-237A>T	N/A	Intron Variant
CYP3A5 transcript variant 3	NR_033807.3:n.	N/A	Splice Acceptor Variant

Gene: ZSCAN25, zinc finger and SCAN domain containing 25 (plus strand)

Molecule type	Change	Amino acid[Codon]	SO Term
ZSCAN25 transcript variant 2	NM_001350979.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 3	NM_001350980.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 4	NM_001350981.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 5	NM_001350982.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 6	NM_001350983.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 7	NM_001350984.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 8	NM_001350985.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 9	NM_001350986.2:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant 1	NM_145115.3:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X1	XM_011515905.3:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X2	XM_011515907.3:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X8	XM_011515909.3:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X11	XM_011515910.3:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X5	XM_047420011.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X3	XM_047420012.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X4	XM_047420013.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X6	XM_047420014.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X7	XM_047420015.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X9	XM_047420016.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X10	XM_047420017.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X13	XM_047420018.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X14	XM_047420019.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X15	XM_047420020.1:c.	N/A	Genic Downstream Transcript Variant
ZSCAN25 transcript variant X16	XR_007059988.1:n.	N/A	Intron Variant
ZSCAN25 transcript variant X17	XR_007059989.1:n.	N/A	Intron Variant
ZSCAN25 transcript variant X18	XR_007059990.1:n.	N/A	Intron Variant
ZSCAN25 transcript variant X12	XR_927402.3:n.	N/A	Intron Variant

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: T= (allele ID: 227764 )

ClinVar Accession	Disease Names	Clinical Significance
RCV000830072.9	not provided	Benign

Allele: C (allele ID: 20105 )

ClinVar Accession	Disease Names	Clinical Significance
RCV000005370.3	Hypertension, salt-sensitive essential, susceptibility to	Risk-Factor
RCV002227926.2	refractory myasthenia gravis	Association
RCV002292440.3	Tacrolimus response	Drug-Response

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement	T=	A	C	G
GRCh38.p14 chr 7	NC_000007.14:g.99672916=	NC_000007.14:g.99672916T>A	NC_000007.14:g.99672916T>C	NC_000007.14:g.99672916T>G
GRCh37.p13 chr 7	NC_000007.13:g.99270539C>T	NC_000007.13:g.99270539C>A	NC_000007.13:g.99270539=	NC_000007.13:g.99270539C>G
CYP3A5 RefSeqGene (LRG_1431)	NG_007938.2:g.12083=	NG_007938.2:g.12083A>T	NG_007938.2:g.12083A>G	NG_007938.2:g.12083A>C
CYP3A5 transcript variant 1	NM_000777.3:c.219-237G>A	NM_000777.3:c.219-237G>T	NM_000777.3:c.219-237=	NM_000777.3:c.219-237G>C
CYP3A5 transcript variant 1	NM_000777.5:c.219-237=	NM_000777.5:c.219-237A>T	NM_000777.5:c.219-237A>G	NM_000777.5:c.219-237A>C
CYP3A5 transcript variant 2	NM_001190484.1:c.219-237G>A	NM_001190484.1:c.219-237G>T	NM_001190484.1:c.219-237=	NM_001190484.1:c.219-237G>C
CYP3A5 transcript variant 2	NM_001190484.3:c.219-237=	NM_001190484.3:c.219-237A>T	NM_001190484.3:c.219-237A>G	NM_001190484.3:c.219-237A>C
CYP3A5 transcript variant 5	NM_001291830.2:c.189-237=	NM_001291830.2:c.189-237A>T	NM_001291830.2:c.189-237A>G	NM_001291830.2:c.189-237A>C
CYP3A5 transcript variant X1	XM_005250169.1:c.189-237G>A	XM_005250169.1:c.189-237G>T	XM_005250169.1:c.189-237=	XM_005250169.1:c.189-237G>C
CYP3A5 transcript variant X5	XM_005250173.1:c.-331-237G>A	XM_005250173.1:c.-331-237G>T	XM_005250173.1:c.-331-237=	XM_005250173.1:c.-331-237G>C
ZSCAN25 transcript variant X5	XM_005250198.1:c.806-4288C>T	XM_005250198.1:c.806-4288C>A	XM_005250198.1:c.806-4288=	XM_005250198.1:c.806-4288C>G

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

177 SubSNP, 11 Frequency, 4 ClinVar submissions

No	Submitter	Submission ID	Date (Build)
1	KWOK	ss903337	Oct 05, 2000 (86)
2	KWOK	ss1982931	Oct 18, 2000 (87)
3	YUSUKE	ss3226600	Sep 28, 2001 (100)
4	RIKENSNPRC	ss6312290	Feb 20, 2003 (111)
5	WUGSC_SSAHASNP	ss14566641	Dec 05, 2003 (120)
6	BIOVENTURES	ss32476137	May 24, 2005 (125)
7	SI_EXO	ss52056856	Oct 15, 2006 (127)
8	EGP_SNPS	ss60197479	Oct 15, 2006 (127)
9	AFFY	ss66208782	Nov 30, 2006 (127)
10	ILLUMINA	ss66852111	Nov 30, 2006 (127)
11	ILLUMINA	ss67828254	Nov 30, 2006 (127)
12	ILLUMINA	ss67989704	Nov 30, 2006 (127)
13	PHARMGKB_PAAR-UCHI	ss68756186	May 17, 2007 (127)
14	PHARMGKB_PAAR-SJCRH	ss69364200	May 17, 2007 (127)
15	PHARMGKB_CREATE	ss69364341	May 17, 2007 (127)
16	PHARMGKB_PAAR-SJCRH	ss69365065	May 17, 2007 (127)
17	PHARMGKB_PAAR-SJCRH	ss69365774	May 17, 2007 (127)
18	PHARMGKB_APP	ss69366578	May 17, 2007 (127)
19	PHARMGKB_APP	ss69366579	May 17, 2007 (127)
20	PHARMGKB_COBRA	ss69367769	May 17, 2007 (127)
21	PHARMGKB_COBRA	ss69369042	May 17, 2007 (127)
22	PHARMGKB_COBRA	ss69370431	May 17, 2007 (127)
23	PHARMGKB_PAAR-UCHI	ss69371750	May 17, 2007 (127)
24	ILLUMINA	ss70948612	May 24, 2008 (130)
25	ILLUMINA	ss71554232	May 17, 2007 (127)
26	ILLUMINA	ss75886836	Dec 07, 2007 (129)
27	AFFY	ss76304543	Dec 07, 2007 (129)
28	ILLUMINA	ss79269303	Dec 15, 2007 (130)
29	HGSV	ss79734120	Dec 15, 2007 (130)
30	KRIBB_YJKIM	ss83560736	Dec 15, 2007 (130)
31	PHARMGKB_PAAR-UCHI	ss84151966	Dec 15, 2007 (130)
32	PHARMGKB_AB_DME	ss84155156	Dec 15, 2007 (130)
33	HGSV	ss85388822	Dec 15, 2007 (130)
34	BGI	ss104454157	Feb 04, 2009 (130)
35	PHARMGKB_PAAR-UCHI	ss105109712	Feb 04, 2009 (130)
36	PHARMGKB_PAAR-UCHI	ss105110081	Feb 04, 2009 (130)
37	SNP500CANCER	ss105439789	Feb 04, 2009 (130)
38	1000GENOMES	ss114159336	Jan 25, 2009 (130)
39	ILLUMINA-UK	ss116216734	Feb 14, 2009 (130)
40	ILLUMINA	ss122830137	Dec 01, 2009 (131)
41	ILLUMINA	ss154445949	Dec 01, 2009 (131)
42	ILLUMINA	ss159620783	Dec 01, 2009 (131)
43	ILLUMINA	ss160912644	Dec 01, 2009 (131)
44	PHARMGKB_PAAR-UCHI	ss161109926	Dec 01, 2009 (131)
45	COMPLETE_GENOMICS	ss164958373	Jul 04, 2010 (132)
46	ILLUMINA	ss172344473	Jul 04, 2010 (132)
47	AFFY	ss173194831	Jul 04, 2010 (132)
48	ILLUMINA	ss174537978	Jul 04, 2010 (132)
49	BUSHMAN	ss197977036	Jul 04, 2010 (132)
50	1000GENOMES	ss223228512	Jul 14, 2010 (132)
51	1000GENOMES	ss234092936	Jul 15, 2010 (132)
52	1000GENOMES	ss241025085	Jul 15, 2010 (132)
53	ILLUMINA	ss244310845	Jul 04, 2010 (132)
54	GMI	ss279457201	May 04, 2012 (137)
55	PJP	ss293932705	May 09, 2011 (134)
56	ILLUMINA	ss481668847	May 04, 2012 (137)
57	ILLUMINA	ss481699564	May 04, 2012 (137)
58	ILLUMINA	ss482666858	Sep 08, 2015 (146)
59	ILLUMINA	ss485629045	May 04, 2012 (137)
60	ILLUMINA	ss537511643	Sep 08, 2015 (146)
61	TISHKOFF	ss560183998	Apr 25, 2013 (138)
62	SSMP	ss654585676	Apr 25, 2013 (138)
63	ILLUMINA	ss778712864	Aug 21, 2014 (142)
64	ILLUMINA	ss783260126	Aug 21, 2014 (142)
65	ILLUMINA	ss784213577	Aug 21, 2014 (142)
66	ILLUMINA	ss825599821	Apr 01, 2015 (144)
67	ILLUMINA	ss832521031	Apr 01, 2015 (144)
68	ILLUMINA	ss833131704	Aug 21, 2014 (142)
69	ILLUMINA	ss833722532	Aug 21, 2014 (142)
70	ILLUMINA	ss834172056	Aug 21, 2014 (142)
71	EVA-GONL	ss984590250	Aug 21, 2014 (142)
72	JMKIDD_LAB	ss1074831453	Aug 21, 2014 (142)
73	1000GENOMES	ss1326338104	Aug 21, 2014 (142)
74	DDI	ss1431222423	Apr 01, 2015 (144)
75	EVA_DECODE	ss1594169240	Apr 01, 2015 (144)
76	EVA_UK10K_ALSPAC	ss1618799238	Apr 01, 2015 (144)
77	EVA_UK10K_TWINSUK	ss1661793271	Apr 01, 2015 (144)
78	EVA_SVP	ss1712974424	Apr 01, 2015 (144)
79	ILLUMINA	ss1752702680	Sep 08, 2015 (146)
80	HAMMER_LAB	ss1805132755	Sep 08, 2015 (146)
81	WEILL_CORNELL_DGM	ss1927851289	Feb 12, 2016 (147)
82	ILLUMINA	ss1959035656	Feb 12, 2016 (147)
83	GENOMED	ss1970771439	Jul 19, 2016 (147)
84	JJLAB	ss2024608477	Sep 14, 2016 (149)
85	EVA	ss2137544478	Oct 31, 2024 (157)
86	USC_VALOUEV	ss2152830326	Dec 20, 2016 (150)
87	HUMAN_LONGEVITY	ss2296201246	Dec 20, 2016 (150)
88	SYSTEMSBIOZJU	ss2626796213	Nov 08, 2017 (151)
89	ILLUMINA	ss2634638281	Nov 08, 2017 (151)
90	ILLUMINA	ss2635175218	Nov 08, 2017 (151)
91	GRF	ss2708540895	Nov 08, 2017 (151)
92	ILLUMINA	ss2711117332	Nov 08, 2017 (151)
93	ILLUMINA	ss2711117333	Nov 08, 2017 (151)
94	GNOMAD	ss2856765814	Nov 08, 2017 (151)
95	AFFY	ss2985413734	Nov 08, 2017 (151)
96	AFFY	ss2986045878	Nov 08, 2017 (151)
97	SWEGEN	ss3001707615	Nov 08, 2017 (151)
98	ILLUMINA	ss3022760766	Nov 08, 2017 (151)
99	BIOINF_KMB_FNS_UNIBA	ss3026096631	Nov 08, 2017 (151)
100	CSHL	ss3347752654	Nov 08, 2017 (151)
101	ILLUMINA	ss3629873044	Oct 12, 2018 (152)
102	ILLUMINA	ss3632543898	Oct 12, 2018 (152)
103	ILLUMINA	ss3633472123	Oct 12, 2018 (152)
104	ILLUMINA	ss3634197474	Oct 12, 2018 (152)
105	ILLUMINA	ss3635132977	Oct 12, 2018 (152)
106	ILLUMINA	ss3635877057	Oct 12, 2018 (152)
107	ILLUMINA	ss3636867363	Oct 12, 2018 (152)
108	ILLUMINA	ss3637630071	Oct 12, 2018 (152)
109	ILLUMINA	ss3638713097	Oct 12, 2018 (152)
110	ILLUMINA	ss3639358346	Oct 12, 2018 (152)
111	ILLUMINA	ss3639707597	Oct 12, 2018 (152)
112	ILLUMINA	ss3640840269	Oct 12, 2018 (152)
113	ILLUMINA	ss3643647679	Oct 12, 2018 (152)
114	URBANLAB	ss3648711027	Oct 12, 2018 (152)
115	ILLUMINA	ss3653294788	Oct 12, 2018 (152)
116	ILLUMINA	ss3654175347	Oct 12, 2018 (152)
117	EGCUT_WGS	ss3669463601	Jul 13, 2019 (153)
118	EVA_DECODE	ss3720300975	Jul 13, 2019 (153)
119	ILLUMINA	ss3726465323	Jul 13, 2019 (153)
120	ACPOP	ss3734902530	Jul 13, 2019 (153)
121	ILLUMINA	ss3745433005	Jul 13, 2019 (153)
122	EVA	ss3766925190	Jul 13, 2019 (153)
123	ILLUMINA	ss3772925856	Jul 13, 2019 (153)
124	KHV_HUMAN_GENOMES	ss3810096692	Jul 13, 2019 (153)
125	EVA	ss3830722362	Apr 26, 2020 (154)
126	EVA	ss3844314999	Apr 26, 2020 (154)
127	HGDP	ss3847885143	Apr 26, 2020 (154)
128	SGDP_PRJ	ss3867981636	Apr 26, 2020 (154)
129	KRGDB	ss3915271030	Apr 26, 2020 (154)
130	KOGIC	ss3962189647	Apr 26, 2020 (154)
131	EVA	ss3984592431	Apr 26, 2021 (155)
132	EVA	ss3985311218	Apr 26, 2021 (155)
133	EVA	ss4017349819	Apr 26, 2021 (155)
134	TOPMED	ss4756565471	Apr 26, 2021 (155)
135	TOMMO_GENOMICS	ss6081190841	Oct 31, 2024 (157)
136	EVA	ss6241635311	Oct 31, 2024 (157)
137	EVA	ss6301280605	Oct 31, 2024 (157)
138	EVA	ss6321947363	Oct 31, 2024 (157)
139	EVA	ss6322314984	Oct 31, 2024 (157)
140	EVA	ss6331469510	Oct 31, 2024 (157)
141	YEGNASUBRAMANIAN_LAB	ss6340796322	Oct 31, 2024 (157)
142	EVA	ss6349711455	Oct 31, 2024 (157)
143	EVA	ss6350127422	Oct 31, 2024 (157)
144	EVA	ss6350127423	Oct 31, 2024 (157)
145	EVA	ss6350127424	Oct 31, 2024 (157)
146	EVA	ss6350127425	Oct 31, 2024 (157)
147	KOGIC	ss6374329865	Oct 31, 2024 (157)
148	GNOMAD	ss6431768256	Oct 31, 2024 (157)
149	GNOMAD	ss6431768257	Oct 31, 2024 (157)
150	GNOMAD	ss6763864749	Oct 31, 2024 (157)
151	TOMMO_GENOMICS	ss8184663009	Oct 31, 2024 (157)
152	QINSY-LAB	ss8237630498	Oct 31, 2024 (157)
153	1000G_HIGH_COVERAGE	ss8274032071	Oct 31, 2024 (157)
154	EVA	ss8315266717	Oct 31, 2024 (157)
155	EVA	ss8375496984	Oct 31, 2024 (157)
156	HUGCELL_USP	ss8471003136	Oct 31, 2024 (157)
157	EVA	ss8509064485	Oct 31, 2024 (157)
158	1000G_HIGH_COVERAGE	ss8562813208	Oct 31, 2024 (157)
159	SANFORD_IMAGENETICS	ss8624670294	Oct 31, 2024 (157)
160	SANFORD_IMAGENETICS	ss8643587318	Oct 31, 2024 (157)
161	TOMMO_GENOMICS	ss8725375030	Oct 31, 2024 (157)
162	EVA	ss8799403419	Oct 31, 2024 (157)
163	EVA	ss8799732140	Oct 31, 2024 (157)
164	YY_MCH	ss8808925638	Oct 31, 2024 (157)
165	EVA	ss8823255906	Oct 31, 2024 (157)
166	EVA	ss8847323008	Oct 31, 2024 (157)
167	EVA	ss8848146824	Oct 31, 2024 (157)
168	EVA	ss8856021519	Oct 31, 2024 (157)
169	EVA	ss8860087635	Oct 31, 2024 (157)
170	EVA	ss8935876044	Oct 31, 2024 (157)
171	EVA	ss8972771770	Oct 31, 2024 (157)
172	EVA	ss8979835149	Oct 31, 2024 (157)
173	EVA	ss8981325937	Oct 31, 2024 (157)
174	EVA	ss8981430112	Oct 31, 2024 (157)
175	EVA	ss8981974722	Oct 31, 2024 (157)
176	EVA	ss8981974723	Oct 31, 2024 (157)
177	EVA	ss8982567034	Oct 31, 2024 (157)
178	1000Genomes_30X	NC_000007.14 - 99672916	Oct 31, 2024 (157)
179	gnomAD v4 - Exomes Submission ignored due to conflicting rows: Row 27083055 (NC_000007.14:99672915:T:A 2/1106432) Row 27083056 (NC_000007.14:99672915:T:C 999214/1106016)	-	Oct 31, 2024 (157)
180	gnomAD v4 - Exomes Submission ignored due to conflicting rows: Row 27083055 (NC_000007.14:99672915:T:A 2/1106432) Row 27083056 (NC_000007.14:99672915:T:C 999214/1106016)	-	Oct 31, 2024 (157)
181	gnomAD v4 - Genomes	NC_000007.14 - 99672916	Oct 31, 2024 (157)
182	HapMap	NC_000007.14 - 99672916	Apr 26, 2020 (154)
183	Korean Genome Project	NC_000007.14 - 99672916	Apr 26, 2020 (154)
184	Korean Genome Project 4K	NC_000007.14 - 99672916	Oct 31, 2024 (157)
185	PharmGKB Aggregated	NC_000007.14 - 99672916	Apr 26, 2020 (154)
186	38KJPN	NC_000007.14 - 99672916	Oct 31, 2024 (157)
187	TopMed	NC_000007.14 - 99672916	Apr 26, 2021 (155)
188	ALFA	NC_000007.14 - 99672916	Oct 31, 2024 (157)
189	ClinVar	RCV000005370.3	Oct 17, 2022 (156)
190	ClinVar	RCV000830072.9	Oct 31, 2024 (157)
191	ClinVar	RCV002227926.2	Oct 17, 2022 (156)
192	ClinVar	RCV002292440.3	Oct 31, 2024 (157)

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Associated ID	History Updated (Build)
rs10361242	Feb 27, 2004 (120)
rs11266830	Apr 05, 2004 (121)
rs58244770	May 24, 2008 (130)
rs386613022	Aug 21, 2014 (142)

Added to this RefSNP Cluster:

Submission IDs	Observation SPDI	Canonical SPDI	Source RSIDs
ss6349711455	NC_000007.13:99270538:C:A	NC_000007.14:99672915:T:A
ss6431768256	NC_000007.14:99672915:T:A	NC_000007.14:99672915:T:A
ss79734120, ss85388822, ss3639358346, ss3639707597	NC_000007.11:98915189:C:C	NC_000007.14:99672915:T:C	(self)
ss114159336, ss116216734, ss164958373, ss197977036, ss279457201, ss293932705, ss481668847, ss825599821, ss1594169240, ss1712974424, ss2635175218, ss3643647679, ss3847885143	NC_000007.12:99108474:C:C	NC_000007.14:99672915:T:C	(self)
ss223228512, ss234092936, ss241025085, ss481699564, ss482666858, ss485629045, ss537511643, ss560183998, ss654585676, ss778712864, ss783260126, ss784213577, ss832521031, ss833131704, ss833722532, ss834172056, ss984590250, ss1074831453, ss1326338104, ss1431222423, ss1618799238, ss1661793271, ss1752702680, ss1805132755, ss1927851289, ss1959035656, ss1970771439, ss2024608477, ss2152830326, ss2626796213, ss2634638281, ss2708540895, ss2711117332, ss2711117333, ss2856765814, ss2985413734, ss2986045878, ss3001707615, ss3022760766, ss3347752654, ss3629873044, ss3632543898, ss3633472123, ss3634197474, ss3635132977, ss3635877057, ss3636867363, ss3637630071, ss3638713097, ss3640840269, ss3653294788, ss3654175347, ss3669463601, ss3734902530, ss3745433005, ss3766925190, ss3772925856, ss3830722362, ss3867981636, ss3915271030, ss3984592431, ss3985311218, ss4017349819, ss6241635311, ss6301280605, ss6322314984, ss6331469510, ss6340796322, ss6349711455, ss8184663009, ss8237630498, ss8315266717, ss8375496984, ss8509064485, ss8624670294, ss8643587318, ss8799403419, ss8799732140, ss8823255906, ss8847323008, ss8848146824, ss8935876044, ss8972771770, ss8979835149, ss8981325937, ss8981430112, ss8981974722, ss8981974723, ss8982567034	NC_000007.13:99270538:C:C	NC_000007.14:99672915:T:C	(self)
RCV000005370.3, RCV002227926.2, RCV002292440.3, 50339143, 290766636, 3455298, 18567648, 24181763, 11635, 98566661, 593943030, 11304204624, ss2137544478, ss2296201246, ss3026096631, ss3648711027, ss3720300975, ss3726465323, ss3810096692, ss3844314999, ss3962189647, ss4756565471, ss6081190841, ss6321947363, ss6350127422, ss6350127423, ss6350127424, ss6350127425, ss6374329865, ss6431768257, ss6763864749, ss8274032071, ss8471003136, ss8562813208, ss8725375030, ss8808925638, ss8856021519, ss8860087635	NC_000007.14:99672915:T:C	NC_000007.14:99672915:T:C	(self)
ss14566641	NT_007933.13:24504122:C:C	NC_000007.14:99672915:T:C	(self)
ss52056856	NT_007933.14:24504814:C:C	NC_000007.14:99672915:T:C	(self)
ss903337, ss1982931, ss3226600, ss6312290, ss32476137, ss60197479, ss66208782, ss66852111, ss67828254, ss67989704, ss68756186, ss69364200, ss69364341, ss69365065, ss69365774, ss69366578, ss69366579, ss69367769, ss69369042, ss69370431, ss69371750, ss70948612, ss71554232, ss75886836, ss76304543, ss79269303, ss83560736, ss84151966, ss84155156, ss104454157, ss105109712, ss105110081, ss105439789, ss122830137, ss154445949, ss159620783, ss160912644, ss161109926, ss172344473, ss173194831, ss174537978, ss244310845	NT_007933.15:37303381:C:C	NC_000007.14:99672915:T:C	(self)
ss6349711455	NC_000007.13:99270538:C:G	NC_000007.14:99672915:T:G

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

498 citations for rs776746

PMID	Title	Author	Year	Journal
12694072	Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms.	Zheng H et al.	2003	American journal of transplantation
12966368	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.	Hesselink DA et al.	2003	Clinical pharmacology and therapeutics
14578760	Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.	Thervet E et al.	2003	Transplantation
14747421	Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.	Zheng H et al.	2004	Journal of clinical pharmacology
15167702	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.	Haufroid V et al.	2004	Pharmacogenetics
15226679	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.	Goto M et al.	2004	Pharmacogenetics
15502717	Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.	Tsuchiya N et al.	2004	Transplantation
15521904	MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.	Mai I et al.	2004	British journal of clinical pharmacology
15707415	Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.	Anglicheau D et al.	2005	American journal of transplantation
15729180	Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians.	Macphee IA et al.	2005	Transplantation
15808586	Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.	Zhao Y et al.	2005	Transplantation proceedings
15919447	Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.	Tada H et al.	2005	Transplantation proceedings
16146556	Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.	Zhang X et al.	2005	Clinical transplantation
16172230	Risk of testicular germ cell cancer in relation to variation in maternal and offspring cytochrome p450 genes involved in catechol estrogen metabolism.	Starr JR et al.	2005	Cancer epidemiology, biomarkers & prevention
16249748	Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.	Mourad M et al.	2005	Transplantation
16421475	Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation.	Yu S et al.	2006	Transplantation
16424824	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.	Uesugi M et al.	2006	Pharmacogenetics and genomics
16501005	Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.	Dai Y et al.	2006	Drug metabolism and disposition
16628701	Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.	Wei-lin W et al.	2006	Liver transplantation
16753004	Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.	Cheung CY et al.	2006	Pharmacogenomics
16815317	CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.	Le Meur Y et al.	2006	Clinical pharmacology and therapeutics
16906020	Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.	Roy JN et al.	2006	Pharmacogenetics and genomics
17015051	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.	Fukudo M et al.	2006	Clinical pharmacology and therapeutics
17032130	The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function.	Mourad M et al.	2006	Clinical chemistry and laboratory medicine
17049058	CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.	Haufroid V et al.	2006	American journal of transplantation
17192769	CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.	Renders L et al.	2007	Clinical pharmacology and therapeutics
17391324	Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.	Choi JH et al.	2007	British journal of clinical pharmacology
17430486	Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients.	Ferraresso M et al.	2007	Pediatric transplantation
17495880	CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.	Kuypers DR et al.	2007	Clinical pharmacology and therapeutics
17568575	Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.	Li D et al.	2007	Clinica chimica acta; international journal of clinical chemistry
17615053	Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.	Bethke L et al.	2007	BMC cancer
17635182	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.	Op den Buijsch RA et al.	2007	Fundamental & clinical pharmacology
17875118	Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.	Li D et al.	2007	Journal of clinical pharmacy and therapeutics
18248681	Prevalence of common disease-associated variants in Asian Indians.	Pemberton TJ et al.	2008	BMC genetics
18334918	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.	Hesselink DA et al.	2008	Pharmacogenetics and genomics
18341670	Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.	Suzuki Y et al.	2008	British journal of clinical pharmacology
18429967	Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.	Satoh S et al.	2008	British journal of clinical pharmacology
18443548	The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.	Tirelli S et al.	2008	Medical science monitor
18547414	Genotyping panel for assessing response to cancer chemotherapy.	Dai Z et al.	2008	BMC medical genomics
18566991	Joint effects of inflammation and androgen metabolism on prostate cancer severity.	Rebbeck TR et al.	2008	International journal of cancer
18589174	Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.	Loh PT et al.	2008	Transplantation proceedings
18784455	The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.	Gupta SK et al.	2008	AIDS (London, England)
18825162	Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.	Perera MA et al.	2009	The pharmacogenomics journal
19067682	Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.	Quteineh L et al.	2008	Basic & clinical pharmacology & toxicology
19076156	Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.	Ekhart C et al.	2009	British journal of clinical pharmacology
19125240	CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.	Satoh S et al.	2009	European journal of clinical pharmacology
19154420	The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.	Liptrott NJ et al.	2009	British journal of pharmacology
19258929	Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.	Press RR et al.	2009	Therapeutic drug monitoring
19289993	The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.	Provenzani A et al.	2009	Annals of transplantation
19343327	Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.	Singh R et al.	2009	Naunyn-Schmiedeberg's archives of pharmacology
19376514	Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.	Su HI et al.	2010	Fertility and sterility
19384171	Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.	Jun KR et al.	2009	Transplantation
19545678	Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.	Chen JS et al.	2009	Transplantation proceedings
19584153	Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.	Kim DH et al.	2009	Clinical cancer research
19694740	No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.	Keskitalo JE et al.	2009	British journal of clinical pharmacology
19865079	Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.	Zhao W et al.	2009	Clinical pharmacology and therapeutics
19907160	CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.	Bhatnagar V et al.	2010	American journal of nephrology
19916993	A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.	Mukonzo JK et al.	2009	British journal of clinical pharmacology
19934400	Genetic predictors of interindividual variability in hepatic CYP3A4 expression.	Lamba V et al.	2010	The Journal of pharmacology and experimental therapeutics
20041908	The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.	Kniepeiss D et al.	2011	Clinical transplantation
20170205	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.	Staatz CE et al.	2010	Clinical pharmacokinetics
20214406	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.	Staatz CE et al.	2010	Clinical pharmacokinetics
20354687	Explaining variability in ciclosporin exposure in adult kidney transplant recipients.	Press RR et al.	2010	European journal of clinical pharmacology
20368718	The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.	Zhu HJ et al.	2011	The pharmacogenomics journal
20383212	Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.	Yanagisawa R et al.	2011	Bone marrow transplantation
20386561	Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.	Wang D et al.	2011	The pharmacogenomics journal
20389299	Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.	Xu CF et al.	2010	British journal of cancer
20393454	Optimization of initial tacrolimus dose using pharmacogenetic testing.	Thervet E et al.	2010	Clinical pharmacology and therapeutics
20415563	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.	Capron A et al.	2010	Pharmacogenomics
20459744	Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.	Gor PP et al.	2010	Breast cancer research
20479955	Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.	Katsakiori PF et al.	2010	International journal of medical sciences
20505666	Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.	Woillard JB et al.	2010	Clinical pharmacology and therapeutics
20538623	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.	Yang X et al.	2010	Genome research
20696882	Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.	Chou M et al.	2010	Antimicrobial agents and chemotherapy
20818295	Differential impact of the CYP3A51 and CYP3A53 alleles on pre-dose concentrations of two tacrolimus formulations.	Wehland M et al.	2011	Pharmacogenetics and genomics
20818834	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.	Benkali K et al.	2010	Clinical pharmacokinetics
20847277	Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification.	Baak-Pablo R et al.	2010	The Journal of molecular diagnostics
20921971	Mapping genes that predict treatment outcome in admixed populations.	Baye TM et al.	2010	The pharmacogenomics journal
20959500	Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.	Smith NF et al.	2010	The Annals of pharmacotherapy
20970601	Genetic polymorphisms and individualized tacrolimus dosing.	López-Montenegro Soria MA et al.	2010	Transplantation proceedings
21047202	Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.	Wang P et al.	2010	Pharmacogenomics
21058046	Genetics of salt-sensitive hypertension.	Sanada H et al.	2011	Current hypertension reports
21072155	Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients.	Ashavaid T et al.	2010	Indian journal of nephrology
21076384	CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.	Min SI et al.	2010	Transplantation
21094796	Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.	Rong G et al.	2010	Transplantation proceedings
21094797	Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients.	Zhang J et al.	2010	Transplantation proceedings
21102498	Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.	Onizuka M et al.	2011	Bone marrow transplantation
21122163	The pharmacogenetics of imanitib.	Dulucq S et al.	2010	Genome medicine
21206424	Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.	Jacobson PA et al.	2011	Transplantation
21219401	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.	Barraclough KA et al.	2011	British journal of clinical pharmacology
21273673	Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.	Turolo S et al.	2010	Pharmacological reports
21289622	Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.	Sadee W et al.	2011	Clinical pharmacology and therapeutics
21331500	Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.	Li L et al.	2011	European journal of clinical pharmacology
21359226	The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected.	Pena SD et al.	2011	PloS one
21359536	Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.	Zhang X et al.	2011	European journal of clinical pharmacology
21366650	Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.	Miura M et al.	2011	Journal of clinical pharmacy and therapeutics
21434840	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.	Picard N et al.	2011	Expert opinion on drug metabolism & toxicology
21436775	Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.	Wu P et al.	2011	Annals of transplantation
21480817	Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.	Tavira B et al.	2011	Clinical chemistry and laboratory medicine
21480951	Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.	Lim JS et al.	2011	British journal of clinical pharmacology
21528942	Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.	Glowacki F et al.	2011	Clinical pharmacokinetics
21544031	Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.	Metalidis C et al.	2011	Transplantation
21566507	CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance.	Pashaee N et al.	2011	Therapeutic drug monitoring
21635144	Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.	Miura M et al.	2011	Pharmacogenomics
21671989	Dosing equation for tacrolimus using genetic variants and clinical factors.	Passey C et al.	2011	British journal of clinical pharmacology
21677300	CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.	Glowacki F et al.	2011	Nephrology, dialysis, transplantation
21698374	The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.	de Wildt SN et al.	2011	European journal of clinical pharmacology
21711429	Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids.	Ferraris JR et al.	2011	Pediatric transplantation
21738081	PharmGKB summary: carbamazepine pathway.	Thorn CF et al.	2011	Pharmacogenetics and genomics
21770725	The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.	de Jonge H et al.	2011	Pharmacogenomics
21806386	Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.	Santoro A et al.	2011	Pharmacogenomics
21839244	Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.	Jordán de Luna C et al.	2011	Transplantation proceedings
21851254	Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.	Ferraresso M et al.	2011	Clinical and experimental hypertension (New York, N.Y.
21886016	Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.	Tang HL et al.	2011	Pharmacogenetics and genomics
21896346	Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation.	Koh Y et al.	2012	Biology of blood and marrow transplantation
21903774	A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.	Elens L et al.	2011	Clinical chemistry
21916909	Association of ABCB1, CYP3A418B and CYP3A53 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.	Shi XJ et al.	2011	Journal of clinical pharmacy and therapeutics
21918509	Pharmacogenomics: application to the management of cardiovascular disease.	Johnson JA et al.	2011	Clinical pharmacology and therapeutics
21922127	Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.	Provenzani A et al.	2011	International journal of molecular medicine
21930396	Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.	Gijsen V et al.	2011	The Journal of heart and lung transplantation
21935354	Phased whole-genome genetic risk in a family quartet using a major allele reference sequence.	Dewey FE et al.	2011	PLoS genetics
21950641	Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.	Shin J et al.	2011	Pharmacotherapy
21955043	Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort.	Oetting WS et al.	2011	Transplant international
21998633	Functional evaluation of genetic and environmental regulators of p450 mRNA levels.	Wang D et al.	2011	PloS one
22006096	Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver.	Schröder A et al.	2013	The pharmacogenomics journal
22007612	Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.	Kim IS et al.	2012	British journal of clinical pharmacology
22015057	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.	Garcia-Donas J et al.	2011	The Lancet. Oncology
22075549	Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers.	Xue L et al.	2011	Pharmacology
22094953	Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.	Sam WJ et al.	2011	Transplantation
22101623	The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.	Stratta P et al.	2012	European journal of clinical pharmacology
22108237	The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.	Birdwell KA et al.	2012	Pharmacogenetics and genomics
22111602	Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.	Brown KC et al.	2012	Pharmacogenomics
22120734	Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.	Rosales A et al.	2012	Clinica chimica acta; international journal of clinical chemistry
22162992	Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.	Yimer G et al.	2011	PloS one
22183771	Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.	Kim IW et al.	2012	European journal of clinical pharmacology
22210422	Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.	Muraki Y et al.	2011	Annals of transplantation
22212486	Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials.	Ganapathi RN et al.	2011	Genome medicine
22304537	Frequencies of CYP3A51/3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients.	Elmachad M et al.	2012	Genetic testing and molecular biomarkers
22310591	Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.	Cho JH et al.	2012	Transplantation proceedings
22339449	Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.	Monchaud C et al.	2012	Clinical pharmacokinetics
22369694	Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.	Gervasini G et al.	2012	Transplant international
22422348	Unusual high dose of tacrolimus in liver transplant patient, a case report.	Provenzani A et al.	2012	International journal of clinical pharmacy
22445700	The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.	Haas DM et al.	2012	American journal of obstetrics and gynecology
22469198	Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients.	Kim IW et al.	2012	Basic & clinical pharmacology & toxicology
22527101	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.	Hertz DL et al.	2012	Breast cancer research and treatment
22660440	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.	Han N et al.	2013	European journal of clinical pharmacology
22702493	Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.	Seredina TA et al.	2012	BMC medical genetics
22704849	CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.	García-Roca P et al.	2012	Archives of medical research
22706623	Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.	Zhao W et al.	2013	European journal of clinical pharmacology
22786571	The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.	Terrazzino S et al.	2012	Pharmacogenetics and genomics
22808112	Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.	Mugusi S et al.	2012	PloS one
22871995	In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.	de Jonge H et al.	2012	Clinical pharmacology and therapeutics
22871999	Concordance of DMET plus genotyping results with those of orthogonal genotyping methods.	Fernandez CA et al.	2012	Clinical pharmacology and therapeutics
22886152	ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.	García M et al.	2013	European journal of clinical pharmacology
22889968	Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients.	Hirano K et al.	2012	Clinica chimica acta; international journal of clinical chemistry
22912647	Liver expression quantitative trait loci: a foundation for pharmacogenomic research.	Glubb DM et al.	2012	Frontiers in genetics
22912756	Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.	Boudou-Rouquette P et al.	2012	PloS one
22992668	Pharmacogenomics knowledge for personalized medicine.	Whirl-Carrillo M et al.	2012	Clinical pharmacology and therapeutics
22992768	Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.	Ji E et al.	2012	Transplantation
23033116	Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.	Savic RM et al.	2012	Clinical pharmacology and therapeutics
23036011	Shared ancestral susceptibility to colorectal cancer and other nutrition related diseases.	Huhn S et al.	2012	BMC medical genetics
23049672	Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.	Bochud M et al.	2011	Current pharmacogenomics and personalized medicine
23064017	Donor ABCB1 variant associates with increased risk for kidney allograft failure.	Moore J et al.	2012	Journal of the American Society of Nephrology
23073208	Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.	Zheng S et al.	2012	Clinical pharmacology and therapeutics
23073467	Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.	Sam WJ et al.	2012	Transplantation
23073468	Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.	Niioka T et al.	2012	Transplantation
23091730	Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.	Fernandez P et al.	2012	Prostate cancer
23104099	Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.	Bertrand J et al.	2012	Pharmacogenetics and genomics
23130019	Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.	Roco A et al.	2012	Frontiers in genetics
23133420	Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.	Suarez-Kurtz G et al.	2012	Frontiers in pharmacology
23139720	Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer.	Kim KS et al.	2012	Experimental and therapeutic medicine
23143606	Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.	Tang NL et al.	2013	Journal of cancer research and clinical oncology
23146466	Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.	Torio A et al.	2012	Transplantation proceedings
23146479	Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.	Díaz-Molina B et al.	2012	Transplantation proceedings
23149441	Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.	Ro H et al.	2012	Therapeutic drug monitoring
23175667	Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.	Bosó V et al.	2013	Drug metabolism and disposition
23252947	Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.	Puranik YG et al.	2013	Pharmacogenomics
23272163	SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.	Singh O et al.	2012	PloS one
23278282	Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.	Chitnis SD et al.	2013	Xenobiotica; the fate of foreign compounds in biological systems
23305195	A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.	Boughton O et al.	2013	British journal of clinical pharmacology
23354298	CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.	Zheng S et al.	2013	Transplantation
23358850	Genetic variants in sex hormone metabolic pathway genes and risk of esophageal squamous cell carcinoma.	Hyland PL et al.	2013	Carcinogenesis
23364483	CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).	Yoon SH et al.	2013	Transplantation
23438946	Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.	Zuo XC et al.	2013	Drug metabolism and pharmacokinetics
23459029	Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.	Zuo XC et al.	2013	Pharmacogenetics and genomics
23462807	Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.	Beuselinck B et al.	2013	British journal of cancer
23501331	Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.	Willrich MA et al.	2013	Clinica chimica acta; international journal of clinical chemistry
23503447	Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.	Zhang X et al.	2013	Therapeutic drug monitoring
23556452	Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.	Krens SD et al.	2013	Pharmacogenomics
23557867	CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.	Li DY et al.	2013	International journal of clinical pharmacology and therapeutics
23580812	Combined approach with therapeutic drug monitoring and pharmacogenomics in renal transplant recipients.	Manvizhi S et al.	2013	Indian journal of nephrology
23584898	CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.	Wang BS et al.	2013	Tumour biology
23588314	CYP3A5 genotype, but not CYP3A41b, CYP3A422, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.	Santoro AB et al.	2013	Clinical pharmacology and therapeutics
23633119	Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.	Ogasawara K et al.	2013	Clinical pharmacokinetics
23666583	CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.	Spierings N et al.	2013	Therapeutic drug monitoring
23687222	Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.	Vardhanabhuti S et al.	2013	The Journal of infectious diseases
23719583	Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.	Kerns SL et al.	2013	Radiotherapy and oncology
23733010	Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.	Niioka T et al.	2013	European journal of clinical pharmacology
23734777	Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy.	Blondon M et al.	2013	Journal of thrombosis and haemostasis
23738951	Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.	Jalil MH et al.	2014	British journal of clinical pharmacology
23778326	A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.	Tavira B et al.	2013	Pharmacogenetics and genomics
23837476	Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.	Durand P et al.	2013	Pharmacogenomics
23837477	CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients.	Gijsen VM et al.	2013	Pharmacogenomics
23861838	Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.	Ngaimisi E et al.	2013	PloS one
23876492	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.	DeGorter MK et al.	2013	Circulation. Cardiovascular genetics
23894093	Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.	Carcas-Sansuán AJ et al.	2013	Liver transplantation
23900887	Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.	Gómez-Bravo MA et al.	2013	Journal of clinical pharmacology
23922006	PharmGKB summary: cyclosporine and tacrolimus pathways.	Barbarino JM et al.	2013	Pharmacogenetics and genomics
23990505	A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.	Sy SK et al.	2013	The AAPS journal
23991193	Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.	Chen D et al.	2013	PloS one
24019753	Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.	Sensorn I et al.	2013	Pharmacogenomics and personalized medicine
24024898	Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.	de Jonge H et al.	2013	Pharmacogenomics
24033383	Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus.	Hirai F et al.	2014	Journal of gastroenterology and hepatology
24089074	Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.	Bergmann TK et al.	2014	Therapeutic drug monitoring
24104197	Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure.	Court MH et al.	2014	Drug metabolism and disposition
24118098	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.	Elens L et al.	2014	British journal of clinical pharmacology
24118301	Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.	Åsberg A et al.	2013	Transplant international
24120259	Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.	Vannaprasaht S et al.	2013	Clinical therapeutics
24126681	Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance.	Werk AN et al.	2014	Clinical pharmacology and therapeutics
24231473	The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.	Shilbayeh S et al.	2013	Saudi journal of kidney diseases and transplantation
24232128	Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population.	Bosó V et al.	2014	Therapeutic drug monitoring
24238261	Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.	Han N et al.	2014	Basic & clinical pharmacology & toxicology
24240480	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.	Kim KA et al.	2014	Pharmacogenetics and genomics
24297552	Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.	Oetjens M et al.	2014	Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
24351870	Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.	Chen D et al.	2014	Drug metabolism and pharmacokinetics
24352002	Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases.	Tanaka K et al.	2014	Journal of human genetics
24368493	Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.	Chi LF et al.	2014	Neuroreport
24378577	Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.	Buendia JA et al.	2014	Therapeutic drug monitoring
24383873	Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients.	Hamzah S et al.	2014	Canadian journal of physiology and pharmacology
24427273	Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population.	Suarez-Kurtz G et al.	2014	PloS one
24435759	Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study.	Lapeyraque AL et al.	2014	Pediatric nephrology (Berlin, Germany)
24438215	CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.	Xue F et al.	2014	Pediatric transplantation
24444408	CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.	Kurzawski M et al.	2014	Pharmacogenomics
24452065	Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus.	Ionita IA et al.	2014	Therapeutic drug monitoring
24465960	Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.	Li CJ et al.	2014	PloS one
24491308	Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.	Cartwright R et al.	2014	European urology
24522145	Effect of CYP3A422, CYP3A53, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.	Moes DJ et al.	2014	CPT
24526611	Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.	Gérard C et al.	2014	The AAPS journal
24528196	Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.	Cusinato DA et al.	2014	British journal of clinical pharmacology
24535486	CHRNA3 and CYP3A5*3 genotype, lung function and chronic obstructive pulmonary disease in the general population.	Kaur-Knudsen D et al.	2014	Pharmacogenetics and genomics
24557078	Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.	Johnson DH et al.	2014	Pharmacogenetics and genomics
24598718	Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.	Tsamandouras N et al.	2014	Clinical pharmacology and therapeutics
24625991	The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients.	Shilbayeh S et al.	2014	Saudi journal of kidney diseases and transplantation
24655974	Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5.	Wu MJ et al.	2014	Transplantation proceedings
24656015	Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.	Hattori Y et al.	2014	Transplantation proceedings
24658827	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.	Lunde I et al.	2014	European journal of clinical pharmacology
24691060	Association of CYP3A418B and CYP3A53 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients.	Xin HW et al.	2014	International journal of clinical pharmacology and therapeutics
24739669	CYP3A53 and POR28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.	Lesche D et al.	2014	Therapeutic drug monitoring
24762860	Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.	Cresci S et al.	2014	Circulation. Cardiovascular genetics
24820765	Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.	Wang Z et al.	2014	European journal of clinical pharmacology
24875272	Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.	Lalan S et al.	2014	Pediatric nephrology (Berlin, Germany)
24884825	Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics.	Li J et al.	2014	BMC genetics
24911663	Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.	Uesugi M et al.	2014	Pharmacogenetics and genomics
24944790	Screening for 392 polymorphisms in 141 pharmacogenes.	Kim JY et al.	2014	Biomedical reports
25028625	Pharmacogenetics of tacrolimus: ready for clinical translation?	Coto E et al.	2011	Kidney international supplements
25110414	Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.	Panczyk M et al.	2014	World journal of gastroenterology
25141896	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.	Guy-Viterbo V et al.	2014	Pharmacogenomics
25201288	Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.	Rojas L et al.	2015	The pharmacogenomics journal
25266489	Genetic polymorphisms of VIP variants in the Tajik ethnic group of northwest China.	Zhang J et al.	2014	BMC genetics
25271170	Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population.	Fernandes DC et al.	2015	International journal of infectious diseases
25271728	Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.	Bruckmueller H et al.	2015	Therapeutic drug monitoring
25279405	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.	Størset E et al.	2014	British journal of clinical pharmacology
25303300	Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation.	Satoh S et al.	2014	Pharmacogenomics
25310192	Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.	Chen YK et al.	2014	PloS one
25322286	Combined effects of CYP3A51, POR28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.	Kuypers DR et al.	2014	Pharmacogenetics and genomics
25419701	Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations.	Bonifaz-Peña V et al.	2014	PloS one
25487141	Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.	Xing J et al.	2015	European journal of clinical pharmacology
25515134	Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.	Miura Y et al.	2014	BMC cancer
25534367	Genetic polymorphisms of ALOX5AP and CYP3A5 increase susceptibility to ischemic stroke and are associated with atherothrombotic events in stroke patients.	Yi X et al.	2015	Journal of stroke and cerebrovascular diseases
25565672	Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.	Iwamoto T et al.	2015	Therapeutic drug monitoring
25590378	The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.	Knops N et al.	2015	Molecular pharmaceutics
25594874	Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.	Niioka T et al.	2015	International journal of molecular sciences
25673014	The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients.	Tavira B et al.	2015	Journal of human genetics
25690039	Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine.	Zaza G et al.	2015	International journal of molecular sciences
25712187	Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies.	Fan J et al.	2015	Pharmacogenomics
25719551	The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.	Gross-Davis CA et al.	2015	International journal of environmental research and public health
25741362	Use of pharmacogenomics in pediatric renal transplant recipients.	Medeiros M et al.	2015	Frontiers in genetics
25817604	ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.	Naito T et al.	2015	Clinica chimica acta; international journal of clinical chemistry
25839935	CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke.	Yi X et al.	2015	Gene
25846845	Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.	Jacobo-Cabral CO et al.	2015	British journal of clinical pharmacology
25881102	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.	Lambrechts S et al.	2015	BMC pharmacology & toxicology
25894154	Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.	Nair SS et al.	2015	Experimental and clinical transplantation
25934339	Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.	Dong N et al.	2015	Tumour biology
25955319	Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.	Chau CH et al.	2015	PloS one
25966085	Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.	Wang L et al.	2015	Genetics and molecular research
25976223	CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.	Tao XR et al.	2015	European journal of pharmaceutical sciences
25992585	Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia.	Lopes BA et al.	2015	PloS one
26067485	Multigene predictors of tacrolimus exposure in kidney transplant recipients.	Pulk RA et al.	2015	Pharmacogenomics
26091847	Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.	Wang L et al.	2015	BMC genetics
26114223	Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.	de Jonge H et al.	2015	British journal of clinical pharmacology
26176181	Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.	Yang TH et al.	2015	International journal of clinical practice. Supplement
26177012	Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.	Cheng Y et al.	2015	International journal of clinical practice. Supplement
26184414	Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.	Togashi M et al.	2015	European journal of clinical pharmacology
26189776	Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis.	Niioka T et al.	2015	Xenobiotica; the fate of foreign compounds in biological systems
26227094	The genetic polymorphisms of POR28 and CYP3A53 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.	Zhang JJ et al.	2015	International journal of clinical pharmacology and therapeutics
26228923	Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.	Li JL et al.	2015	Pharmacogenomics
26232156	A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus: Towards personalized medicine, immunosuppression and pharmacogenomics.	Millner L et al.	2015	Clinica chimica acta; international journal of clinical chemistry
26271661	Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.	Monostory K et al.	2015	British journal of clinical pharmacology
26300393	Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.	Vaidya S et al.	2015	European journal of pharmacology
26325438	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.	Khaled SK et al.	2016	Biology of blood and marrow transplantation
26421491	Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.	Wang P et al.	2015	Epilepsy research
26423716	Cytochrome P450 Genetic Variants and Their Metabolite Levels Associated with Plaque Stability in Patients with Ischemic Stroke.	Yi XY et al.	2016	Journal of atherosclerosis and thrombosis
26485092	Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.	Oetting WS et al.	2016	American journal of transplantation
26518936	Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.	Argudo A et al.	2015	Transplantation proceedings
26518946	A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period.	Townamchai N et al.	2015	Transplantation proceedings
26521259	Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.	Moes DJ et al.	2016	European journal of clinical pharmacology
26543771	CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.	Li Y et al.	2015	SpringerPlus
26615671	Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.	Aouam K et al.	2015	Pharmacogenomics
26621708	Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline.	Schwarz F et al.	2016	Proceedings of the National Academy of Sciences of the United States of America
26622455	Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.	Stefanović NZ et al.	2015	Experimental and therapeutic medicine
26634478	Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients.	Wang L et al.	2015	Genetics and molecular research
26635230	Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.	Yaowakulpatana K et al.	2016	European journal of clinical pharmacology
26667830	Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.	Sanghavi K et al.	2017	The pharmacogenomics journal
26770526	Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.	Zhu L et al.	2015	International journal of clinical and experimental medicine
26779253	An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.	Swart M et al.	2015	Frontiers in genetics
26784512	Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus.	Yan L et al.	2016	Pharmacogenomics
26801900	Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.	Cocca M et al.	2016	Journal of translational medicine
26823971	The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients.	Zaltzman AS et al.	2016	Transplantation research
26830973	The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.	Qin C et al.	2016	Scientific reports
26858644	Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling.	Chua EW et al.	2016	Frontiers in pharmacology
26882121	A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET(TM) Plus platform.	Choi Y et al.	2017	The pharmacogenomics journal
26915847	Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients.	Mac Guad R et al.	2016	Transplantation proceedings
26933222	Alzheimer's disease CD33 rs3865444 variant does not contribute to cognitive performance.	Liu G et al.	2016	Proceedings of the National Academy of Sciences of the United States of America
26961113	Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.	Yi X et al.	2016	Journal of atherosclerosis and thrombosis
26988277	Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.	Ruan Y et al.	2016	Scientific reports
26990259	Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.	Niioka T et al.	2016	International journal of urology
26990694	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.	Pallet N et al.	2016	American journal of transplantation
26991336	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.	Bienczak A et al.	2016	British journal of clinical pharmacology
27020167	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.	Duran I et al.	2016	Pharmacogenomics
27042114	Effects of CYP3A5 genetic polymorphism and smoking on the prognosis of non-small-cell lung cancer.	Jiang LP et al.	2016	OncoTargets and therapy
27087514	Interactions Among CYP2C8, EPHX2, and CYP4A11 Variants and CYP Plasma Metabolite Levels in Ischemic Stroke.	Yi X et al.	2016	Journal of atherosclerosis and thrombosis
27110018	CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.	Alvarez-Elías AC et al.	2016	Transplantation proceedings
27110117	Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.	Medhasi S et al.	2016	Neuropsychiatric disease and treatment
27138787	Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?	Brooks E et al.	2016	Clinical pharmacokinetics
27171561	Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings.	Voican CS et al.	2016	PloS one
27225724	Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.	Yousef AM et al.	2016	Iranian journal of kidney diseases
27233804	Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.	Jin T et al.	2016	BMC genetics
27294413	Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.	Srivastava AK et al.	2016	Human genomics
27296832	ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.	Fukunaga K et al.	2016	BMC genetics
27314545	CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.	Deininger KM et al.	2016	Clinical transplantation
27320564	Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.	Kato H et al.	2016	Transplantation proceedings
27434656	Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.	Genvigir FD et al.	2016	Pharmacogenetics and genomics
27498208	The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children.	Abo El Fotoh WM et al.	2016	Seizure
27498776	The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.	Liu S et al.	2016	Acta pharmacologica Sinica
27503662	Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.	Miyata Y et al.	2016	Annals of transplantation
27540311	Prevalence of CYP2D62, CYP2D64, CYP2D610, and CYP3A53 in Thai breast cancer patients undergoing tamoxifen treatment.	Charoenchokthavee W et al.	2016	Breast cancer (Dove Medical Press)
27564227	Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.	Numakura K et al.	2017	Anti-cancer drugs
27707991	Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.	Bienczak A et al.	2017	The Journal of antimicrobial chemotherapy
27717793	The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus.	Asada A et al.	2017	Digestive and liver disease
27757045	Pharmacogenomics of statins: understanding susceptibility to adverse effects.	Kitzmiller JP et al.	2016	Pharmacogenomics and personalized medicine
27767381	The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment.	Sortica VA et al.	2016	Pharmacogenomics
27780519	International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.		2016	Journal of the International AIDS Society
27904761	Vincristine-induced peripheral neuropathy in pediatric cancer patients.	Mora E et al.	2016	American journal of cancer research
28049954	No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.	Li M et al.	2017	Biological & pharmaceutical bulletin
28061365	Primer design for SNP genotyping based on allele-specific amplification-Application to organ transplantation pharmacogenomics.	Tortajada-Genaro LA et al.	2017	Journal of pharmaceutical and biomedical analysis
28084894	Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients.	Ren L et al.	2017	Pharmacogenomics
28112181	IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.	Liu MZ et al.	2017	Acta pharmacologica Sinica
28178648	Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.	Kuo SH et al.	2017	Oncotarget
28229376	The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.	Madsen MJ et al.	2017	Drugs in R&D
28246425	Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients.	Zhang X et al.	2017	Disease markers
28346074	Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.	Hertz DL et al.	2017	Pharmacogenomics
28408884	Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.	Liu S et al.	2017	Frontiers in pharmacology
28435308	Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients.	Salgado PC et al.	2017	Pharmacogenomics and personalized medicine
28448186	Association between CYP3A5 genotypes with hypertension in Chinese Han population: A case-control study.	Li Z et al.	2017	Clinical and experimental hypertension (New York, N.Y.
28500872	CYP3A genes and the association between prenatal methylmercury exposure and neurodevelopment.	Llop S et al.	2017	Environment international
28533324	CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.	Dorr CR et al.	2017	Drug metabolism and disposition
28621555	SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients.	Liu Y et al.	2017	Biomarkers in medicine
28673292	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.	Mutagonda RF et al.	2017	Malaria journal
28685716	Gene Variations of Sixth Complement Component Affecting Tacrolimus Metabolism in Patients with Liver Transplantation for Hepatocellular Carcinoma.	Liao JH et al.	2017	Chinese medical journal
28727815	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.	Pascual T et al.	2017	PloS one
28812116	SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.	Liu JE et al.	2017	European journal of clinical pharmacology
28869324	Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs.	Varnell CD et al.	2017	Pediatric transplantation
28941036	Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation.	Zhang T et al.	2018	Liver international
28952408	Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.	Sun B et al.	2017	Pharmacogenomics
29193749	Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years.	Borobia AM et al.	2018	Clinical and translational science
29256966	Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.	Gómez-Bravo MA et al.	2018	Pharmacogenetics and genomics
29399716	Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.	Lancia P et al.	2018	Pediatric nephrology (Berlin, Germany)
29427770	Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.	Cargnin S et al.	2018	Pharmacological research
29454235	Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.	Liu J et al.	2018	International immunopharmacology
29606886	Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.	Kryukov AV et al.	2018	Pharmacogenomics and personalized medicine
29652911	Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.	Jmel H et al.	2018	PloS one
29665413	Genetic risk factors for post-transplantation diabetes mellitus in Chinese Han renal allograft recipients treated with tacrolimus.	Zhang X et al.	2018	Transplant immunology
29668485	Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.	Raimondi A et al.	2018	Anti-cancer drugs
29691392	Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study.	DeBoever C et al.	2018	Nature communications
29775201	Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients.	Campagne O et al.	2018	Journal of clinical pharmacology
29792121	ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.	Werbrouck E et al.	2019	Acta clinica Belgica
29950882	CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.	Denisenko NP et al.	2018	Pharmacogenomics and personalized medicine
29970707	Association of CYP3A5*3 polymorphisms and prostate cancer risk: A meta-analysis.	Liang Y et al.	2018	Journal of cancer research and therapeutics
29998574	CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.	Holmberg MT et al.	2019	Clinical pharmacology and therapeutics
30045320	Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.	Lu Q et al.	2018	Medicine
30068618	Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.	Collin LJ et al.	2018	BMJ open
30093869	Biological Predictors of Clozapine Response: A Systematic Review.	Samanaite R et al.	2018	Frontiers in psychiatry
30130726	UHPLC-MS/MS method for determination of atorvastatin calcium in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype.	Xia B et al.	2018	Journal of pharmaceutical and biomedical analysis
30393497	The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients.	Belohlavkova P et al.	2018	Archives of medical science
30537010	TLR9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period.	Ou B et al.	2019	Pharmacotherapy
30595243	Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.	Ramakumari N et al.	2018	Indian heart journal
30801552	Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.	Oetting WS et al.	2019	Transplantation
30953600	Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.	Mohamed ME et al.	2019	American journal of transplantation
31019283	Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests.	Thauvin-Robinet C et al.	2019	European journal of human genetics
31086207	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.	Afsar NA et al.	2019	Scientific reports
31087280	The Effects of CYP3A5 Genetic Polymorphisms on Serum Tacrolimus Dose-Adjusted Concentrations and Long-Term Prognosis in Chinese Heart Transplantation Recipients.	Liu BY et al.	2019	European journal of drug metabolism and pharmacokinetics
31137904	Inter-Individual Variability in Xenobiotic-Metabolizing Enzymes: Implications for Human Aging and Longevity.	Crocco P et al.	2019	Genes
31214251	Genome-Wide Association Study of Tacrolimus Pharmacokinetics Identifies Novel Single Nucleotide Polymorphisms in the Convalescence and Stabilization Periods of Post-transplant Liver Function.	Liu Y et al.	2019	Frontiers in genetics
31219197	The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome.	Coller JK et al.	2019	British journal of clinical pharmacology
31269327	Genetic Contribution in Low Back Pain: A Prospective Genetic Association Study.	Margarit C et al.	2019	Pain practice
31401678	CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.	Liu H et al.	2019	European journal of clinical pharmacology
31617197	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.	Sychev D et al.	2019	High blood pressure & cardiovascular prevention
31880588	Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.	Ghafari S et al.	2019	Iranian journal of kidney diseases
31893292	The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.	Belderbos BPS et al.	2020	Cancer chemotherapy and pharmacology
31993939	Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.	Sawaki A et al.	2020	International journal of hematology
32146629	CYP3A Polymorphism and Chronic Mercury Intoxication.	Chernyak YI et al.	2020	Bulletin of experimental biology and medicine
32149782	Sex Bias and Genotype Influence on Opioid Safety Profile in Chronic Low Back Pain.	Margarit C et al.	2020	The Clinical journal of pain
32158254	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.	Sychev DA et al.	2020	Pharmacogenomics and personalized medicine
32253660	Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy.	Zou X et al.	2020	International journal of clinical pharmacy
32256016	Importance of genetic polymorphisms in liver transplantation outcomes.	Kelava T et al.	2020	World journal of gastroenterology
32260456	A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMET(TM) Plus Platform.	Gim JA et al.	2020	International journal of molecular sciences
32279544	Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients.	Torres Espíndola LM et al.	2020	Biomarkers
32298597	CYP Genotypes Are Associated with Toxicity and Survival in Osteosarcoma Patients.	Trujillo-Paolillo A et al.	2020	Journal of adolescent and young adult oncology
32326111	Role of Genetic Variations in the Hepatic Handling of Drugs.	Marin JJG et al.	2020	International journal of molecular sciences
32351149	Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.	Ahern TP et al.	2020	Acta oncologica (Stockholm, Sweden)
32366712	Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax.	Almeida ACG et al.	2020	Antimicrobial agents and chemotherapy
32457635	Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.	Liao D et al.	2020	Frontiers in pharmacology
32459809	Unique insights from ClinicalTrials.gov by mining protein mutations and RSids in addition to applying the Human Phenotype Ontology.	Alag S et al.	2020	PloS one
32477124	Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico.	Galaviz-Hernández C et al.	2020	Frontiers in pharmacology
32639515	Bayesian Pathway Analysis for Complex Interactions.	Baurley JW et al.	2020	American journal of epidemiology
32657689	CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.	Muller WK et al.	2020	South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
32780457	Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.	Udagawa C et al.	2020	Cancer science
32847973	Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors.	Chiorean EG et al.	2020	Molecular cancer therapeutics
32849848	Beyond Single Nucleotide Polymorphisms: CYP3A5(∗)3(∗)6(∗)7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients.	Brazeau DA et al.	2020	Frontiers in genetics
32872162	Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450.	Hlaváč V et al.	2020	Journal of personalized medicine
33144648	Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation.	Mauleekoonphairoj J et al.	2020	Scientific reports
33217013	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.	Yip VLM et al.	2021	British journal of clinical pharmacology
33238394	VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study.	Gal J et al.	2020	Pharmaceuticals (Basel, Switzerland)
33280091	Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis.	Wojtyniak JG et al.	2021	Clinical pharmacology and therapeutics
33291741	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.	Maillard M et al.	2020	Cancers
33386894	The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.	Wu Y et al.	2021	European journal of clinical pharmacology
33398393	CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.	Everton JBF et al.	2021	European journal of clinical pharmacology
33423267	[Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction].	Qi L et al.	2021	Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
33430289	Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans.	Han N et al.	2021	Journal of personalized medicine
33519226	Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.	Fernandes MR et al.	2021	Pharmacogenomics and personalized medicine
33564260	Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension.	Liang H et al.	2021	Pharmacogenomics and personalized medicine
33638195	The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.	Flores-Pérez C et al.	2021	Journal of clinical pharmacy and therapeutics
33646566	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.	Sallustio BC et al.	2021	British journal of clinical pharmacology
33755393	An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients.	Min S et al.	2022	Transplantation
33756436	Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.	Zhao GX et al.	2021	Epilepsy research
33762959	Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.	Sun F et al.	2021	Frontiers in pharmacology
33804537	Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.	Iannaccone T et al.	2021	Pharmaceuticals (Basel, Switzerland)
33805706	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.	Zubiaur P et al.	2021	Journal of personalized medicine
33829662	Genetic variants related to successful migraine prophylaxis with verapamil.	Cutrer FM et al.	2021	Molecular genetics & genomic medicine
33995083	Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism.	Mejía-Abril G et al.	2021	Frontiers in pharmacology
34053421	Frequency of ABCB1 C3435T and CYP3A5*3 Genetic Polymorphisms in the Lebanese Population.	Milane A et al.	2021	Experimental and clinical transplantation
34150864	Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.	Yang X et al.	2021	Frontiers in cardiovascular medicine
34241984	Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.	Friebus-Kardash J et al.	2022	Transplantation
34262462	Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia.	Kaehler M et al.	2021	Frontiers in pharmacology
34284341	Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.	Li L et al.	2021	International immunopharmacology
34382722	Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.	Ndadza A et al.	2021	Journal of thrombosis and haemostasis
34385834	Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process.	Borro M et al.	2021	Pharmacogenomics and personalized medicine
34429635	Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population.	He C et al.	2021	Pharmacogenomics and personalized medicine
34434063	Genetic Polymorphisms of Pesticide-Metabolizing Enzymes and Transporters in Agricultural Workers and Thyroid Hormone Levels.	Sirivarasai J et al.	2021	Risk management and healthcare policy
34563731	Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease.	Das SK et al.	2021	Molecular metabolism
34603785	Assessment of the Link of ABCB1 and NR3C1 gene polymorphisms with the prednisolone resistance in pediatric nephrotic syndrome patients of Bangladesh: A genotype and haplotype approach.	Parvin MN et al.	2021	Journal of advanced research
34621706	Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.	Kim B et al.	2021	Translational and clinical pharmacology
34688813	CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.	Dong Y et al.	2022	Gene
34689350	Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.	Qi G et al.	2022	Clinical and experimental pharmacology & physiology
34690761	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.	Villapalos-García G et al.	2021	Frontiers in pharmacology
34798807	Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.	Li D et al.	2021	BMC genomic data
34802160	Machine learning-based method for tacrolimus dose predictions in Chinese kidney transplant perioperative patients.	Fu Q et al.	2022	Journal of clinical pharmacy and therapeutics
34899282	Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients.	Miranda C et al.	2021	Frontiers in pharmacology
34949935	Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China.	Wang Y et al.	2021	Pharmacogenomics and personalized medicine
34958284	Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.	Muyambo S et al.	2022	Omics
34974452	The Impact of Donor and Recipient Genetic Variation on Outcomes After Solid Organ Transplantation: A Scoping Review and Future Perspectives.	Li Y et al.	2022	Transplantation
35089958	Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.	Goljan E et al.	2022	PloS one
35091749	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa.	Haas DW et al.	2022	The Journal of infectious diseases
35135554	Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.	Gao B et al.	2022	BMC medical genomics
35158880	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis.	Uittenboogaard A et al.	2022	Cancers
35228813	Prediction of Tacrolimus Dose/Weight-Adjusted Trough Concentration in Pediatric Refractory Nephrotic Syndrome: A Machine Learning Approach.	Mo X et al.	2022	Pharmacogenomics and personalized medicine
35338956	ABCG2, SCN1A and CYP3A5 genes polymorphism and drug-resistant epilepsy in children: A case-control study.	Mousavi SF et al.	2022	Seizure
35471917	CYP3A422 and CYP3A53 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome.	Skryabin VY et al.	2023	Nordic journal of psychiatry
35497687	The Prevalence of Pharmacogenomics Variants and Their Clinical Relevance Among the Pakistani Population.	Khan AR et al.	2022	Evolutionary bioinformatics online
35501422	Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.	Hjorth CF et al.	2022	Breast cancer research and treatment
35570009	Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients-Preliminary Report.	Warzyszyńska K et al.	2022	Transplantation proceedings
35761855	Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.	Nthontho KC et al.	2022	Pharmacogenomics and personalized medicine
35839255	Association of cytochromes P450 3A422 and 3A53 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.	Elalem EG et al.	2022	PloS one
35879888	Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients.	Warzyszyńska K et al.	2022	Annals of transplantation
35892315	Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.	Guijosa A et al.	2022	Clinical and translational science
35995116	Genetic polymorphisms of pharmacogenomic VIP variants in the Lahu population from Yunnan Province.	Dou X et al.	2022	Gene
36065758	CYP2C83 and 4 define CYP2C8 phenotype: An approach with the substrate cinitapride.	Campodónico DM et al.	2022	Clinical and translational science
36145636	Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants.	Yoon HY et al.	2022	Pharmaceutics
36164570	Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.	Alshabeeb MA et al.	2022	Saudi pharmaceutical journal
36248867	Genetic factors underlying tacrolimus intolerance after liver transplantation.	Liu Y et al.	2022	Frontiers in immunology
36256705	Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.	Sychev DA et al.	2022	Pharmacogenetics and genomics
36309848	Effect of Genotype on the Pharmacokinetics and Bleeding Events of Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.	Shi J et al.	2023	Journal of clinical pharmacology
36362548	Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers.	Nuchjumroon A et al.	2022	Journal of clinical medicine
36598552	The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.	Hjorth CF et al.	2023	Cancer chemotherapy and pharmacology
36632298	Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review.	Rajabi-Moghaddam M et al.	2022	Reports of practical oncology and radiotherapy
36660495	Pilot study: genetic distribution of AR, FGF5, SULT1A1 and CYP3A5 polymorphisms in male Mexican population with androgenetic alopecia.	Martinez-Chapoy D et al.	2022	International journal of molecular epidemiology and genetics
36827667	Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series.	Šimičević L et al.	2023	Pharmacy (Basel, Switzerland)
37228580	Immunogenetics and pharmacogenetics of allergic asthma in Africa.	Mabelane T et al.	2023	Frontiers in allergy

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:

Select flank length:

Genomic regions, transcripts, and products
Top▲ Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Choose placement

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

Reference SNP (rs) Report

rs776746